If H5N1 bird flu ever achieves sustained human transmission, the pandemic toll may not fall equally across all age groups — and the reason traces back to which influenza strain a person first encountered in childhood. Understanding who already carries partial immune defenses against avian H5N1 could fundamentally reshape how public health authorities allocate vaccines and antiviral stockpiles in a future outbreak.
A 2024 cross-sectional serosurvey of 575 British Columbians, spanning ages 1 to over 80, measured neuraminidase inhibition antibody titers against the currently circulating clade 2.3.4.4b H5N1 virus alongside two human pandemic strains. Roughly 70% of participants showed detectable cross-reactive anti-N1 antibodies against H5N1 at a threshold titer of ≥10, with 45% reaching the more protective ≥40 level. The distribution was strikingly non-uniform: young adults born between 1997 and 2003 — school-age children during the 2009 H1N1 pandemic — carried the highest H5N1 cross-reactive titers, while middle-aged adults imprinted during the 1957–1967 H2N2 era showed the weakest responses. Oldest participants imprinted on pre-1947 H1N1 strains displayed a secondary antibody peak, mirroring the young-adult pattern. The correlation between H1N1pdm09 and H5N1 anti-N1 titers was exceptionally strong (r = 0.86), confirming that N1 neuraminidase exposure — not hemagglutinin — is the principal driver of this cross-protection.
This work extends the "original antigenic sin" or immunological imprinting framework from hemagglutinin research into neuraminidase territory, an underappreciated arm of influenza immunity. Neuraminidase antibodies are increasingly recognized as correlates of protection independent of hemagglutinin-blocking immunity, yet most pandemic preparedness models still center on hemagglutinin. The finding that H2N2-imprinted cohorts — roughly today's 57–67-year-olds — carry the lowest cross-reactive N1 titers is epidemiologically significant, potentially flagging a vulnerable middle-aged demographic. Key limitations include the observational, cross-sectional design, the inability to establish causality between titer levels and clinical protection, and the single-province sampling frame. Whether these antibody levels translate into reduced hospitalization or mortality risk during actual H5N1 exposure remains unconfirmed. Still, the granularity of birth-cohort stratification makes this an incrementally important contribution to pandemic risk modeling.